Scisparc Ltd surges 26.43% amid market context
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 26 Dec 25
Source: Coinmarketcap
Scisparc Ltd's stock price has surged by 26.43% in pre-market trading, as it crosses above the 5-day SMA, indicating a strong upward momentum.
This significant price movement occurs amid broader market weakness, with the Nasdaq-100 down 0.01% and the S&P 500 down 0.03%. The stock's rise suggests sector rotation as investors may be shifting their focus to biotech companies, which could be benefiting from recent developments in the sector.
The implications of this surge could indicate a growing interest in Scisparc Ltd. as investors look for opportunities in a challenging market environment, potentially positioning the company for future growth.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
